In association with known clinicopathologic parameters, the status of FOXC1‐positive stromal cells and pERK1‐2‐positive tumor cells within the DLBCL tumor microenvironment is summarized in Table 1. This evidence concerns the gene FOXC1 and diffuse large B-cell lymphoma.